Clinical trial
CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining…
NCT00330746 · National Cancer Institute, Naples, Other · Completed
Key facts
| NCT number | NCT00330746 |
|---|---|
| Title | CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer |
| Official title | Randomized Phase II Study of Cetuximab in Combination With Gemcitabine or Gemcitabine Followed by Cetuximab in Advanced Non Small-cell Lung Cancer Patients Who Are Not Candidates for Platinum Based Therapy. |
| Acronym | CALC-1 |
| Lead sponsor | National Cancer Institute, Naples, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | cetuximab, gemcitabine |
| Enrollment | 100 |
| Start date | Nov 1, 2005 |
| Primary completion | Jan 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | May 29, 2006 |
| Last update posted | May 18, 2012 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: